Company intelligence / Profile preview
Pola Pharma
Japan
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Pola Pharma developed a portfolio of branded and generic dermatology products, with at least one marketed small molecule drug (carglumic acid, a CPS1 activator) approved in Europe for acidemia indications. It operated two manufacturing sites with capacity for both topical and injectable products. The company's acquisition by Sun Pharma expanded Sun's dermatology business and manufacturing base in Japan[1][2][3][4][5][7].
- Therapeutic areas
- EndocrinologyNeurologyMetabolic DisordersRare DiseasesDermatology
- Modalities
- Small moleculeInjectableTopicalBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Pola Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pola Pharma.